Can a gut metabolite shield the kidneys in IgA nephropathy?

NCT ID NCT07750249

ENROLLING_BY_INVITATION Disease control Sponsor: University Hospital, Martin Source: ClinicalTrials.gov ↗

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This trial tests whether sodium butyrate, a short-chain fatty acid, can reduce protein in the urine and slow kidney function decline in people with IgA nephropathy, a kidney disease. Participants receive either sodium butyrate or a placebo for 12 weeks, then switch after a washout period. The study aims to see if changing the gut microbiome can help manage the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sodium butyrate (a short-chain fatty acid) taken as an oral capsule
What this could lead to: If it works, this could offer a safe, cost-effective way to slow kidney damage in IgA nephropathy, potentially delaying the need for more aggressive treatments.
What could go wrong: This is an early-phase trial, so the benefits are uncertain. The study is relatively small, and sodium butyrate may cause gastrointestinal side effects or may not significantly reduce proteinuria.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY IGA NEPHROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic renal failure syndrome IgA glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY IGA NEPHROPATHY

Contacts and locations

Locations

University Hospital Martin

Martin, 036 01, Slovakia

More trials for these conditions

Other studies related to the condition(s) this trial covers.